DelveInsight’s, “Common Warts Pipeline Insight, 2025,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape. It covers the Common Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Common Warts pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Common Warts Pipeline? Click here to explore the therapies and trials making headlines @ Common Warts Pipeline Outlook Report

Key Takeaways from the Common Warts Pipeline Report

• On 05 September 2025, Nielsen BioSciences Inc. announced a study involves a comparison of an equal volume injection of Candin with an injection of placebo (unpreserved normal saline solution) in common warts. Subjects will be randomized 2:1 to receive Candin or placebo. During the Treatment Period, 1 dose (0.5 mL) of investigational product (IP) will be injected every 2 weeks into a single treatment wart until either clinical clearance of the treatment wart is achieved or a total of 10 injections have been administered.
• DelveInsight’s Common Warts Pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Common Warts treatment.
• The leading Common Warts Companies such as Verrica Pharamceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, NIELSEN BioSciences and others.
• Promising Common Warts Therapies such as A-101, KNP2002, DFD05 Cream, CLS006, Resiquimod, NVN1000 8% Gel, Imiquimod 5% cream, Tirbanibulin ointment 1% and others.

Want to know which companies are leading innovation in Common Warts? Dive into the full pipeline insights @ Common Warts Clinical Trials Assessment

The Common Warts Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Common Warts Pipeline Report also highlights the unmet needs with respect to the Common Warts.

Common Warts Overview

Warts are benign lesions that occur in the mucosa and skin. Warts are caused by the human papillomavirus (HPV), with over 100 types of HPV identified. HPV may occur at any site. The primary manifestations of HPV infection include common warts, genital warts, flat warts, deep palmoplantar warts (Myrmecia), focal epithelial hyperplasia, Epidermodysplasia verruciformis, and Plantar cysts. Warts may be transmitted by direct or indirect contact.

Common Warts Emerging Drugs Profile

• Mavorixafor: X4 Pharmaceuticals

Mavorixafor as an oral, once-daily treatment for patients with WHIM syndrome. WHIM syndrome is a rare genetic primary immunodeficiency that results from “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.

• VP-102: Verrica Pharmaceuticals

VP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.

If you’re tracking ongoing Common Warts Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Common Warts Treatment Drugs

The Common Warts Pipeline report provides insights into:-

• The report provides detailed insights about companies that are developing therapies for the treatment of Common Warts with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Common Warts Treatment.
• Common Warts Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Common Warts Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Common Warts market.

Common Warts Companies

Verrica Pharamceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, NIELSEN BioSciences and others.

Common Warts pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Common Warts Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

From emerging drug candidates to competitive intelligence, the Common Warts Pipeline Report covers it all – check it out now @ Common Warts Market Drivers and Barriers, and Future Perspectives

Scope of the Common Warts Pipeline Report

• Coverage- Global
• Common Warts Companies- Verrica Pharamceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, NIELSEN BioSciences and others.
• Common Warts Therapies- A-101, KNP2002, DFD05 Cream, CLS006, Resiquimod, NVN1000 8% Gel, Imiquimod 5% cream, Tirbanibulin ointment 1% and others.
• Common Warts Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Common Warts Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Common Warts Treatment landscape in this detailed analysis @ Common Warts Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Common Warts: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Common Warts– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Mavorixafor: X4 Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Diphencyprone: Phio Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Common Warts Key Companies
21. Common Warts Key Products
22. Common Warts- Unmet Needs
23. Common Warts- Market Drivers and Barriers
24. Common Warts- Future Perspectives and Conclusion
25. Common Warts Analyst Views
26. Common Warts Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/common-warts-pipeline-insight